ImmunoVax

Executive Summary

ImmunoVax is a clinical-stage biotechnology company developing next-generation cancer vaccines and immunotherapies leveraging a proprietary platform designed to activate the immune system against tumor-specific antigens. Founded in 2018 and headquartered in Philadelphia, the company has raised $220 million in funding to advance its pipeline of novel therapies targeting solid tumors with high unmet need. Its lead programs are in Phase 2 development, aiming to demonstrate durable responses with favorable safety profiles compared to existing standards of care. ImmunoVax's platform has the potential to address multiple cancer types by eliciting robust and long-lasting anti-tumor immunity, positioning the company as a key player in the evolving immuno-oncology landscape. With strong financial backing and a focused clinical strategy, ImmunoVax is poised to deliver value through upcoming clinical milestones and potential strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead cancer vaccine program65% success
• Q4 2026FDA IND clearance for next-generation immunotherapy candidate80% success
• Q1 2027Potential strategic partnership or licensing deal for oncology pipeline50% success